Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACCL0431||COG||A Randomized Phase III Study of Sodium Thiosulfate (IND#72877; NSC#45624) for the Prevention of Cisplatin-Induced Ototoxicity in Children: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|S0819||SWOG||A Randomized; Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY009||NRG||A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0281||GOG||A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer. NCT # NCT02101788||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY005||NRG||A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS)||Adult CIRB - Late Phase Emphasis||Available to Open|
|LungMAP||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-BR004||NRG||A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1Q11||ECOG||EROS: Engendering Reproductive Health within Oncologic Survivorship||Cancer Prevention and Control CIRB||Available to Open|
|EA2161||ECOG-ACRIN||A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|ANHL12P1||COG||A Randomized Phase II Trial of Brentuximab Vedotin (SGN35; NSC# 749710) or Crizotinib (NSC#749005; commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117||Pediatric CIRB||Available to Open|